Clinical Trials

31 enrolled

Small Cell Lung Carcinoma

NCT07358676 2026-01-22

A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung Cancer

25 enrolled

Small Cell Lung Carcinoma

NCT07307443 2025-12-29

A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.

28 enrolled

Lung Neoplasms

NCT07294261 2025-12-19

Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC

69 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04136535 2025-07-22

PCA

105 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06379087 2025-07-10

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

20 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07037680 2025-07-09

Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT

44 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06977828 2025-06-29

A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07022301 2025-06-15

Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy

25 enrolled

Small Cell Lung Cancer Extensive Stage

NCT06978153 2025-05-18

This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Combined With Chemotherapy With or Without Anlotinib in Resectable Limited-Stage Small Cell Lung Cancer

66 enrolled

Limited Stage Small Cell Lung Cancer

NCT06851169 2025-02-28

This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete Response

58 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04691388 2024-12-05

A Trial of Sintilimab Plus Anlotinib For Metastatic NSCLC After First-Line PD-1 Inhibitor

29 enrolled

Phase 2 Active not recruiting

NSCLC

NCT05400070 2024-10-18

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

45 enrolled

Lung Neoplasms

NCT06355609 2024-09-20

WUKONG-32-RW

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06483672 2024-07-03

LungBrain001

27 enrolled

CNSThoracic

Adenocarcinoma of Lung, Brain Neoplasms

NCT06475755 2024-06-26

Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC

178 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06221462 2024-01-25

PRIORITY

30 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03646968 2023-12-27

SAVE

43 enrolled

Non-Squamous Non Small Cell Lung Cancer

NCT06182761 2023-12-27

WUKONG-9

45 enrolled

NSCLC

NCT04790409 2023-09-14

Sintilimab Combined With Anlotinib in Advanced NSCLC With EGFR Uncommon Mutations

21 enrolled

Lung Neoplasms

NCT03743129 2023-06-12

ALTER-L029

90 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05842018 2023-05-03

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

30 enrolled

Non Small Cell Lung Cancer Recurrent

NCT04895930 2023-01-06

FOCUS-A

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05481775 2022-11-21

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Phase 2 Withdrawn

Locally Advanced Non-small Cell Lung Cancer

NCT05485350 2022-08-03

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

32 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05460195 2022-07-15

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

42 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT04660097 2022-04-12

Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer

120 enrolled

Small Cell Lung Carcinoma

NCT05306847 2022-04-01

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

93 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04846452 2021-08-12

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04978753 2021-07-27

the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

54 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03736837 2021-03-15

ALTER-L004

60 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04620837 2020-11-09

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

25 enrolled

Small Cell Lung Carcinoma

NCT04316351 2020-07-23

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

60 enrolled

IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy

NCT04363255 2020-04-28

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

20 enrolled

Small Cell Lung Carcinoma

NCT04358562 2020-04-24

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

240 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04314297 2020-03-19

Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

33 enrolled

Small Cell Lung Carcinoma

NCT03624309 2020-01-07

Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer

84 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04211896 2019-12-26

Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer

70 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03700359 2019-11-29

A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC

60 enrolled

Small Cell Lung Carcinoma

NCT04181372 2019-11-29

A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04164745 2019-11-15

Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer

49 enrolled

NSCLC

NCT03059797 2019-05-16

Study of Anlotinib in Patients With Small Cell Lung Cancer (ALTER1202)

120 enrolled

Small Cell Lung Carcinoma

NCT03841136 2019-03-28

Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer

70 enrolled

Small Cell Lung Carcinoma

NCT03780283 2018-12-21

Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC

30 enrolled

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03778138 2018-12-19

ALTER-L025

51 enrolled

Non-squamous Cell Non-Small Cell Lung Cancer

NCT03765775 2018-12-06

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

20 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03732846 2018-11-07

Anlotinib in Treatment of Recurrent Small Cell Lung Cancer

43 enrolled

Small Cell Lung Carcinoma

NCT03728374 2018-11-02

Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma

38 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03654027 2018-08-31

Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC

84 enrolled